STOCK TITAN

GSK’s velzatinib gets orphan drug designation in Japan

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

GSK plc announced that velzatinib received Orphan Drug Designation in Japan for gastrointestinal stromal tumour (GIST). The designation was supported by phase I/Ib StrateGIST 1 data showing promising anti-tumour activity and a promising tolerability profile. Velzatinib also has US FDA Fast Track designation and Orphan Drug Designations in the US and EU.

Phase III studies are under way in first- and second-line advanced or metastatic GIST. Enrollment in the second-line trial is tracking ahead of schedule, with data expected in the second half of 2027. A separate phase II study, StrateGIST J, is under way in Japan for patients whose disease has progressed or who are intolerant to available treatment options.

CTOS abstracts 7 abstracts Velzatinib-related abstracts to be presented at the CTOS Annual Meeting 2026.
Second-line trial data timing Expected in the second half of 2027 Data from the velzatinib second-line clinical trial.
Annual global GIST diagnoses Approximately 80,000 to 120,000 patients Estimated number of patients diagnosed with GIST globally each year.
GIST cases driven by KIT mutations 80% The filing says this share of GIST cases is driven by KIT mutations.
First-line patients developing new KIT mutations About 90% The filing says this share of patients treated in the first line develop new KIT mutations.
Annual GIST incidence in Japan Approximately 4 per 100,000 people Age-adjusted annual incidence stated for Japan.
Orphan Drug Designation (ODD) regulatory
"received Orphan Drug Designation (ODD) from Japan’s Ministry of Health Labour and Welfare"
Orphan drug designation (ODD) is a regulatory status granted to a medicine intended to treat a rare disease or condition, giving the developer special incentives such as reduced fees, development support, and a period of exclusive market rights. For investors, ODD signals that a product may face less competition, enjoy stronger pricing power, and benefit from lower development costs and regulatory help—similar to receiving a temporary protected license to serve a small but underserved market.
Fast Track designation regulatory
"granted US Food and Drug Administration (FDA) Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
KIT inhibitor medical
"a novel, highly selective KIT inhibitor"
A kit inhibitor is a medicine that blocks the KIT protein, a switch on some cells that tells them to grow and divide. Investors care because drugs that shut off this switch can treat cancers and other diseases driven by KIT; successful kit inhibitors can create new revenue streams but also carry risks from side effects, competition, and resistance—like replacing a faulty thermostat in a building to stop overheating but needing the right fit and maintenance.
tyrosine kinase inhibitors (TKIs) medical
"There are no approved tyrosine kinase inhibitors (TKIs)"
Tyrosine kinase inhibitors (TKIs) are a class of medicines that block specific enzymes—tyrosine kinases—that act like on/off switches controlling cell growth and division; by turning off those switches in abnormal cells, TKIs can slow or stop tumor growth and some other disease processes. Investors care because TKIs drive significant drug sales, face clear clinical trial and regulatory milestones, and can change a company’s revenue outlook quickly if trials succeed or safety issues arise, similar to how a single product can make or break a tech startup.
secondary or resistance mutations medical
"secondary or resistance mutations in exons 13 and 17"
translational biomarkers medical
"work on translational biomarkers"
Translational biomarkers are measurable signs—like a blood test result or imaging feature—that help link laboratory research to patient outcomes, acting as a bridge between early-stage science and real-world treatment effects. For investors they matter because reliable biomarkers can speed development, reduce clinical trial risk, and improve chances of regulatory approval, similar to having a test that predicts whether a new product will work before full-scale production.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will GSK present at the CTOS Annual Meeting 2026?

GSK said seven abstracts will be presented at the meeting in Seoul, South Korea, November 18–21, 2026. They include clinical analyses of velzatinib in first- and second-line GIST by KIT mutation, preclinical research on mutation coverage and work on translational biomarkers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
Issued: 19 November 2026, London UK
 
Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST
 
●
Designation supported by StrateGIST 1 data showing promising anti-tumour activity and tolerability profile
●
Adds to US FDA Fast Track Designation and ODDs in the US and EU
●
Phase III studies accelerated in first- and second-line GIST
  


GSK plc (LSE/NYSE: GSK) today announced that velzatinib, a novel, highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The ODD was supported by data from the ongoing phase I/Ib StrateGIST 1 trial in advanced GIST, which showed promising anti-tumour activity and a promising tolerability profile.[1] In addition to the ODD in Japan, velzatinib has been granted US Food and Drug Administration (FDA) Fast Track designation, and US and European Union (EU) ODD.
 
GSK is accelerating the development of velzatinib, with phase III trials under way in first- and second-line advanced / metastatic GIST.[2],[3] Enrolment in the second-line clinical trial is tracking ahead of schedule, reflecting strong interest in velzatinib from the GIST community, with data expected in the second half of 2027.

Additional data for velzatinib will be shared at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2026 (18-21 November, Seoul, South Korea). Seven abstracts will be presented, including clinical analyses of velzatinib in first- and second-line GIST by KIT mutation, preclinical research on mutation coverage and work on translational biomarkers. These data will further support velzatinib’s development across different KIT mutations and lines of therapy, where resistance and tolerability remain significant challenges.
 
About velzatinib
Velzatinib is a novel, highly selective KIT inhibitor specifically designed for gastrointestinal stromal tumour (GIST). This monotherapy targets all clinically relevant primary and key secondary KIT mutations, addressing a major unmet need in GIST treatment where tolerability is challenging and resistance arises from diverse KIT mutations.
 
About GIST
Gastrointestinal stromal tumour (GIST) is a rare type of cancer most commonly arising in the stomach and small intestine. Globally, approximately 80,000 to 120,000 patients are diagnosed with GIST annually.[4] 80% of GIST cases are driven by mutations in the KIT gene that lead to the growth, proliferation and survival of tumour cells (primary or activating mutations in exons 9 and 11).[5] Additionally, about 90% of patients treated in the 1st-line develop new KIT mutations (secondary or resistance mutations in exons 13 and 17) that typically lead to relapse with limited therapeutic options.[6] There are no approved tyrosine kinase inhibitors (TKIs) that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.
  
In Japan, the age-adjusted annual incidence of GIST is one of the highest in the world, at approximately 4 per 100,000 people.[7] While outcomes for people with GIST have improved over the past two decades, the five-year survival rate remains significantly lower once the disease has spread.[8] An additional phase II trial with velzatinib – StrateGIST J – is underway in Japan, evaluating patients whose disease has progressed, or who are intolerant to available treatment options.[9]

GSK in oncology
GSK is focused on developing differentiated medicines for cancers where patients continue to face poor outcomes, treatment resistance, limited options or significant treatment burden. We focus where advances in science and technology offer the greatest opportunity to improve outcomes across haematological, lung, gastrointestinal, genitourinary and gynaecological cancers. Across multiple modalities, including targeted small molecules, antibody-drug conjugates (ADCs) and immunotherapies, GSK applies deep expertise in cancer biology and immune system science to develop differentiated medicines designed to deliver durable responses, overcome resistance and reduce treatment burden.
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
GSK enquiries
 
 
 
Media:
Tim Foley
+44 (0) 20 8047 5502
(London)
 
Sarah Clements
+44 (0) 20 8047 5502
(London)
 
Kathleen Quinn
+1 202 603 5003
(Washington DC)
 
Alison Hunt
+1 540 742 3391
(Washington DC)
 
 
 
 
Investor Relations:
James Dodwell
+44 (0) 7881 269066
(London)
 
Mick Readey
+44 (0) 7990 339653
(London)
 
Joanna Tuplin
+44 (0) 7788 351650
(London)
 
Sam Piper
+44 (0) 7824 525779
(London)
 
Dan Smith
+44 (0) 7823 523885
(London)
 
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
 
Frannie DeFranco
+1 215 751 3126
(Philadelphia)
 
 
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q3 Results for 2026.
 
 
Registered in England & Wales:
No. 3888792

 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
  
References
[1] Jones RL, Somaiah N, Bauer S, et al. Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by KIT mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study. Presented at ASCO Congress 2026. Abstract #11501.
[2] ClinicalTrials.gov. A study of IDRX-42 (GSK6042981) versus (vs) sunitinib in participants with gastrointestinal stromal tumors after imatinib therapy. Accessed November 2026. Available at: https://clinicaltrials.gov/study/NCT07218926
[3] ClinicalTrials.gov. A study to investigate velzatinib compared with imatinib in adult participants with previously untreated metastatic and/​or unresectable gastrointestinal stromal tumors (StrateGIST Frontline). Accessed November 2026. Available at: https://clinicaltrials.gov/study/NCT07585266.
[4] Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46.
[5] Zhou S, Abdihamid O, Tan F, et al. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Cell Commun Signal. 2024;22(1):153.
[6] Serrano C, Martín-Broto J, Asencio-Pascual JM, et al. 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023;15:17588359231192388
[7] Hirano H, Naito Y, Nishida T, et al. Epidemiologic features and age-related differences in management among patients with gastrointestinal stromal tumors in Japan: A National Cancer Registry Study. Cancer Res Commun. 2025;5(7):1235-1242.
[8]American Cancer Society. Survival rates for gastrointestinal stromal tumors. Accessed November 2026. Available at: https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
[9] ClinicalTrials.gov. A study of velzatinib in participants with metastatic and/​or unresectable GIST after imatinib, sunitinib, regorafenib, and pimitespib. Accessed November 2026. Available at: https://clinicaltrials.gov/study/NCT07689201
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: November 19, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

Keep reading